1. In Vitro Activity of JPC 2067 Alone and in Combination with Sulfamethoxazole against Nocardia Species
- Author
-
Swagatam Mookherjee, Carolyn M. Shoen, and Michael Cynamon
- Subjects
Pharmacology ,Sulfamethoxazole ,biology ,Triazines ,Nocardia Infections ,Nocardia ,Microbial Sensitivity Tests ,Nocardia species ,biology.organism_classification ,In vitro ,Dihydrofolate reductase inhibitor ,Anti-Bacterial Agents ,Microbiology ,Tetrahydrofolate Dehydrogenase ,Infectious Diseases ,Susceptibility ,medicine ,Humans ,Drug Therapy, Combination ,Pharmacology (medical) ,medicine.drug - Abstract
JPC 2067 is a novel dihydrotriazine dihydrofolate reductase inhibitor that is being developed as an antimalarial therapeutic. We evaluated the in vitro activity of JPC 2067 alone and in combination with sulfamethoxazole (SMX) against a panel of nocardia isolates. The MIC 50 s and MIC 90 s for JPC 2067, SMX, and the combination were 0.125 μg/ml and 4 μg/ml, 16 μg/ml and 32 μg/ml, and 0.03 μg/ml and 2 μg/ml, respectively. JPC 2067 alone and in combination with SMX should be evaluated further to understand its clinical potential.
- Published
- 2012
- Full Text
- View/download PDF